Revolution's High Stakes: Pancreatic Cancer and the Price of Innovation The FDA approval of Rasonque (daraxonrasib) for metastatic pancreatic cancer has sent Revolution Medicines' stock soaring.
However, beneath this success lies a complex web of risks and uncertainties.
The clinical benefit of this new therapy is undeniable, but its price tag – now a staggering $47 billion valuation – suggests that investors have already factored in the success of Rasonque.